Verona Pharma PLC (VRNA)
| Market Cap | 388.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -31.94M |
| Shares Out | 105.33M |
| EPS (ttm) | -2.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $7.50 |
| Previous Close | $7.66 |
| Change ($) | -0.16 |
| Change (%) | -2.09% |
| Day's Open | 7.74 |
| Day's Range | 7.50 - 7.73 |
| Day's Volume | 29,501 |
| 52-Week Range | 2.16 - 10.20 |
Top-line results expected in 2Q 2021 Top-line results expected in 2Q 2021
LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, anno...
Non-dilutive capital to provide further financial flexibility Non-dilutive capital to provide further financial flexibility
LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, anno...
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2020 Results - Earnings Call Transcript
Initiated ENHANCE Phase 3 clinical trials in COPD
LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), provides a further update with regards to its intend...
Posters highlight ensifentrine’s potential to provide rapid benefits Posters highlight ensifentrine’s potential to provide rapid benefits
Verona Pharma (VRNA) is developing twice-daily nebulized formulation of ensifentrine as potential maintenance treatment for COPD.
LONDON and RALEIGH, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory ...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS ...
LONDON and RALEIGH, N.C., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory ...
Publication highlights ensifentrine’s potential to provide rapid symptom relief Publication highlights ensifentrine’s potential to provide rapid symptom relief
LONDON and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory ...
LONDON and RALEIGH, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory ...
LONDON and RALEIGH, N.C., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused o...
New subgroup analysis supports ensifentrine’s efficacy in symptomatic COPD patients New subgroup analysis supports ensifentrine’s efficacy in symptomatic COPD patients
Results expected in the first half of 2021 Results expected in the first half of 2021
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q2 2020 Results - Earnings Call Transcript
The small drugmaker reported good news about new clinical studies for its lead pipeline candidate.
Completed $200 million private placement post period
Is (VRNA) Outperforming Other Medical Stocks This Year?
LONDON and RALEIGH, N.C., Aug. 07, 2020 (GLOBE NEWSWIRE) --
Top Ranked Momentum Stocks to Buy for August 6th 2020
LONDON and RALEIGH, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused...
Top Ranked Momentum Stocks to Buy for August 4th
LONDON and RALEIGH, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory d...
Top Ranked Momentum Stocks to Buy for July 31st
LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory d...
Top Ranked Momentum Stocks to Buy for July 29th
Top Ranked Momentum Stocks to Buy for July 28th
As of late, it has definitely been a great time to be an investor of Verona Pharma
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. NE...
LONDON, United Kingdom and RALEIGH, N.C., July 17, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical...
Funding to support Phase 3 ENHANCE clinical program in COPD Funding to support Phase 3 ENHANCE clinical program in COPD
LONDON, July 06, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing in...
LONDON, May 12, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and co...
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q1 2020 Results - Earnings Call Transcript
Analysis supports ensifentrine’s efficacy in COPD as monotherapy and on top of standard of care treatment in patients who remain symptomatic
LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
LONDON, April 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing an...
Statistically significant and clinically meaningful improvements in lung function
Statistically significant and clinically meaningful improvements in lung function
LONDON, March 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing i...
LONDON, March 05, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and ...
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2019 Results - Earnings Call Transcript
Paper demonstrates ensifentrine’s potential in improving lung function and quality of life symptoms Paper demonstrates ensifentrine’s potential in improving lung function and quality of life s...
LONDON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- TR-1: S tandard form for notification of major holdings
Dr. David Zaccardelli appointed President and Chief Executive Officer
About VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical... [Read more...]
| Industry Biotechnology | IPO Date Apr 27, 2017 |
| CEO David Zaccardelli | Employees 33 |
| Stock Exchange NASDAQ | Ticker Symbol VRNA |
Analyst Forecasts
According to 5 analysts, the average rating for Verona Pharma stock is "Strong Buy." The 12-month stock price forecast is 18.80, which is an increase of 150.67% from the latest price.